LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline key results from the 32-week analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results